Pre-eclampsia in 2026: What Frontline Clinicians Should Know

Pre-eclampsia is a multisystem pregnancy disorder associated with major maternal, fetal and neonatal morbidity and mortality. The Lancet Seminar describes it as affecting at least 2–4% of pregnancies, while some estimates extend as high as 8%. The burden is disproportionately high in low-income and middle-income countries, where delayed recognition, limited antenatal surveillance, shortages of trained staff, transport barriers, restricted laboratory access and inconsistent availability of antihypertensives and magnesium sulphate can turn a manageable disorder into a fatal emergency.

The Seminar cites an estimated 46,000 maternal deaths and 500,000 fetal and newborn deaths associated with pre-eclampsia each year. It reports prevalence estimates exceeding 11% in Ethiopia, illustrating the importance of this condition to African frontline practice.

Pre-eclampsia is commonly identified after 20 weeks of gestation and may also develop or first become apparent postpartum, generally within six weeks after birth. It is new-onset hypertension accompanied by one or more of proteinuria, maternal end-organ dysfunction or uteroplacental dysfunction.

Its pathophysiology is heterogeneous. Important mechanisms include abnormal placentation, placental malperfusion, angiogenic imbalance and maternal cardiometabolic susceptibility. Poor placentation is particularly associated with early-onset disease and fetal growth restriction; no single mechanism explains every case.

Major international guidelines have adopted a broader multisystem definition. In a patient with new hypertension after 20 weeks, pre-eclampsia can be diagnosed when there is maternal end-organ dysfunction or uteroplacental dysfunction even if significant proteinuria is absent. Do not delay escalation solely because a urine dipstick is negative.

Apply locally adopted diagnostic thresholds and protocols. Biomarker availability and validated cut-offs vary by setting.

Pre-eclampsia can progress rapidly. Avoid using “mild pre-eclampsia” in a way that creates false reassurance. Terminology differs: some US guidance uses “pre-eclampsia with severe features”, while other international guidance avoids separating the disease into “mild” and “severe”.

History-only prediction models have limited sensitivity. Combined first-trimester screening—where available—can incorporate maternal characteristics, medical history, blood pressure, uterine-artery Doppler and biomarkers. Cost, operator training, equipment calibration, laboratory access and external validation remain important barriers in many African settings.

1. Cardiometabolic health

Pre-conception and antenatal care should address diet quality, appropriate weight management and moderate-intensity physical activity where clinically safe. The Seminar highlights at least 150 minutes of moderate exercise per week as an overall prevention strategy, adapted to individual circumstances.

2. Low-dose aspirin

• Aspirin is intended for pregnant patients identified as being at increased risk of pre-eclampsia.
• The Seminar describes a dose of up to 150 mg at night, most effective when started before 16 weeks.
• It describes discontinuation at 36 weeks, or around 10 days before an earlier planned birth.
• Dose and timing must follow local protocol and individual bleeding-risk assessment. Do not encourage patient self-prescribing.

The ASPRE trial reported a 62% reduction in preterm pre-eclampsia with 150 mg/day in a screened high-risk population. This does not mean aspirin should be given universally.

3. Calcium

Assess dietary context and follow national antenatal guidance. This distinction is particularly important in settings where calcium intake is commonly low.

4. Risk-stratified timed birth at term

Risk-stratified timed birth at term can reduce the occurrence of pre-eclampsia in selected populations. This is a specialist obstetric decision and must not be converted into a universal induction rule.

The Seminar reports benefit from normalising blood pressure towards a diastolic target of approximately 85 mmHg or below 140/90 mmHg, reducing severe hypertension and maternal complications without an observed increase in fetal growth restriction or neonatal admission in those trials. It recommends antihypertensive treatment for all antenatal hypertension.

Use the emergency and maintenance antihypertensive regimen authorised by the clinician’s national or institutional protocol. A universal dosing table is not appropriate because acute and maintenance regimens differ by protocol, formulation, comorbidity and clinical setting. Use cautious fluid management because unnecessary intravascular volume expansion may increase pulmonary oedema.

Magnesium sulphate reduces the occurrence or recurrence of eclampsia by approximately half. It is indicated for eclampsia and is considered for pre-eclampsia with significant risk of seizure or severe complications according to local protocol. It is not universal prophylaxis for every patient with hypertension.

Monitoring should follow local protocol and include respiratory status, deep-tendon reflexes, urine output and renal function, level of consciousness, and availability of calcium gluconate and resuscitation support.

“Delivery” does not automatically mean Caesarean section. Mode of birth depends on obstetric circumstances.

Patients need a documented monitoring and follow-up plan, with home blood-pressure monitoring where feasible and reliable.

Postpartum headache has a broad differential diagnosis and must not automatically be attributed to pre-eclampsia.

Previous pre-eclampsia is an important cardiovascular and renal risk marker. The Seminar reports associations—not guaranteed outcomes—of approximately four-fold increased risk of later hypertension; approximately two-fold increased risks of type 2 diabetes, dyslipidaemia, cardiovascular disease and chronic kidney disease; and approximately three-fold increased risk of end-stage renal disease.

Recurrence occurs in approximately 10–20% of later pregnancies, while about 30% of subsequent pregnancies may be complicated by either gestational hypertension or recurrent pre-eclampsia.

The Seminar recommends confirming resolution of end-organ complications at approximately three months postpartum and continuing longer-term cardiovascular-risk surveillance.

When sophisticated biomarkers and high-dependency facilities are unavailable, basic care must still be done reliably:

1. Measure blood pressure correctly and repeat abnormal measurements.
2. Ask directly about headache, visual symptoms, epigastric pain, reduced fetal movement and breathlessness.
3. Test urine protein when available, while remembering that absence of proteinuria does not rule out the disease.
4. Assess platelets, creatinine, transaminases and fetal wellbeing according to available resources.
5. Treat hypertension promptly using locally approved agents.
6. Give magnesium sulphate when indicated.
7. Avoid harmful fluid loading.
8. Stabilise before transfer whenever possible.
9. Communicate clearly with the referral facility.
10. Do not delay referral while waiting for every investigation when severe disease is clinically apparent.
11. Provide postpartum safety-net instructions before discharge.
12. Record the diagnosis for future primary-care and pregnancy risk assessment.

Vancouver citation: Walker MC, Murphy MSQ, Scremin Souza SC, Koi-Larbi K, Costa ML, Hyett J, von Dadelszen P, Magee LA, Pre-eclampsia Patient Advocacy Collaborator Group. Pre-eclampsia. Lancet. 2026;408. doi:10.1016/S0140-6736(26)01071-8. Published 29 August 2026.